Neogen Corporation
NASDAQ•NEOG
CEO: Mr. John Edward Adent
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Listing Date: 1989-08-23
Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns, as well as food quality and nutritional components. It also provides AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods. The segment offers its products primarily to milling and grain, meat and poultry, prepared food products and ingredients, fruits and vegetables, seafood, dairy, beverage, water, healthcare, traditional culture media markets, food service, and dietary supplements markets. The Animal Safety segment provides veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products, and genomics testing services marketed through veterinarians, retailers, livestock producers, and animal health product distributors, for the animal safety market. The segment offers its products for companion animal veterinarians; livestock producers, veterinarians, and breed associations; retailers; breeding and genetics companies; diagnostic labs and universities; distributors; and other manufacturers and government agencies. The company was incorporated in 1981 and is headquartered in Lansing, Michigan.
Contact Information
Market Cap
$2.07B
P/E (TTM)
-3.4
33.5
Dividend Yield
--
52W High
$11.43
52W Low
$4.46
52W Range
Rank47Top 61.9%
3.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 3.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2026 Data
Revenue
$211.20M+0.00%
4-Quarter Trend
EPS
-$0.08+0.00%
4-Quarter Trend
FCF
$11.07M+0.00%
4-Quarter Trend
2026 Q2 Earnings Highlights
Key Highlights
Net Income Swings to Profit Six months net income $20.41M profit versus $468.89M loss prior year, driven by divestiture gains.
Operating Cash Flow Rises Cash provided by operations $30.30M for six months, increasing $7.96M due to working capital improvements.
Animal Safety Operating Income Animal Safety segment operating income $13.30M, up $11.07M, benefiting from favorable mix and lower restructuring costs.
Divestiture Gain Recognized Recognized $76.39M gain on Cleaners & Disinfectants sale, significantly boosting six-month pre-tax income results.
Risk Factors
Revenue Impacted by Divestiture Total revenues decreased $14.34M (3%) for six months, heavily impacted by Cleaners & Disinfectants divestiture.
Gross Margin Compression Noted Gross margin fell to 46.5% (6 months) due to higher tariffs, inventory write-offs, and Petrifilm manufacturing costs.
Material Internal Control Weakness Management confirmed material weaknesses in internal controls over financial reporting as of November 30, 2025.
Ongoing Shareholder Litigation Facing multiple putative class action lawsuits regarding 3M integration; loss estimation is currently not possible.
Outlook
Capital Spending Focus Estimated $50M capital expenditures for fiscal 2026, focusing $35M on integrating acquired 3M FSD products.
Production Inefficiencies Improving Production inefficiencies in sample collection line continuing in Q1 2026, expecting continued improvement each successive quarter.
Debt Repayment Strategy Used divestiture proceeds to repay debt; no further required principal payments on Term Loan until Q2 2027.
Tax Rule Monitoring Closely monitoring OECD Pillar Two global minimum tax rules; no material top-up tax forecasted for foreign subsidiaries currently.
Peer Comparison
Revenue (TTM)
$2.84B
$1.64B
$1.37B
Gross Margin (Latest Quarter)
100.0%
75.8%
73.9%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| SYRE | $4.41B | -162.8 | -29.4% | 0.0% |
| IMNM | $2.16B | -10.1 | -57.6% | 0.6% |
| NEOG | $2.07B | -3.4 | -29.0% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
-2.2%
Flat Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
100%
Strong Cash Flow
Deep Research
Next earnings:Jul 28, 2026
EPS:$0.07
|Revenue:$212.19M
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement | LTM |
|---|
No Data